A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

Inclusion Criteria Patients must have: * HIV-positive status. * Screening viral load \>= 10,000 copies/mm3 14 days prior to entry. * CD4+ cell counts \>= 200 cells/mm3 14 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinical diagnosis of AIDS (CDC 1993 Classification C). Concurrent Medication: Excluded: Terfenadine, astemizole, cisapride, triazolam, medazolam, and ergotamine/dihydroergotamine-containing regimens. Patients with the following prior conditions are excluded: Clinically relevant hepatitis in the previous 6 months. Prior Medication: Excluded: * Greater than 4 weeks of any nucleoside antiretroviral therapy. * Previous therapy with an HIV protease inhibitor. * Cytotoxic chemotherapeutic agents within 4 weeks prior to entry. * Immunomodulating agents within 3 months prior to entry. Prior Treatment: Excluded: Radiotherapy within 4 weeks prior to entry. Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with the patient's ability to comply with the dosing schedule or protocol evaluations.